In 2019, more than 100 stakeholders met to discuss the challenges of rolling out gene therapy trials in the UK, and to identify what next steps should be taken by the whole DMD community, including doctors, industry professionals and patient advocacy groups. .
You can read more about the discussions and conclusions in the Neuromuscular Disorders Journal.